Internal medicine

Retrospective cohort study

Pediatrics

Disease

Darunavir

Regimen

Population

Coronavirus disease 2019 (COVID-19)

Infectious disease (medical specialty)

Pandemic

Viral load

Virology

Antiretroviral therapy

Protease inhibitor (pharmacology)

Human immunodeficiency virus (HIV)

Medicine

Environmental health

Infection

Data on people living with human immunodeficiency virus (PLWH) in the current SARS-CoV-2 pandemic are still scarce. This case series of 33 PLWH patients with COVID-19 reveals symptoms and outcome in this special population.Retrospective analysis of anonymized data including age, gender, HIV-associated parameters, symptoms, and outcome.Three out of 32 patients with documented outcomes died (9%). 91% of the patients recovered and 76% have been classified as mild cases. All patients were on antiretroviral treatment, of them 22 on tenofovir-containing regimen and 4 on the protease inhibitor darunavir.This preliminary case series does not support excess morbidity and mortality among symptomatic COVID-19 PLWH and with viral suppression on ART. SARS-CoV-2 infections may occur during boosted darunavir-based and/or on tenofovir-containing ART.

COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients